The Inflammatory Mediator/Bronchoscopy Core plays a central role in research in the Cystic Fibrosis Research Core Center by providing the ability to sample directly the inflamed airway in CF patients and control subjects and to study the cells and inflammatory mediators found at that site. It disseminates samples to researchers for whom they might otherwise be unavailable and provides access to sensitive standardized assays of cytokines and lipid-derived inflammatory mediators to Center investigators. This Inflammatory Mediator/Bronchoscopy Core performs the following functions: a) it obtains and processes bronchoalveolar lavage (BAL) samples and bronchial epithelial cells obtained by bronchoscopy brushing from CF patients and normal volunteers; b) it provides appropriately handled epithelial and inflammatory cells and fluid samples from these bronchoscopies and lavages to Center investigators for investigators of immune and inflammatory processes in CF, and coordinates the efforts of Center investigators to optimize the use of these invaluable specimens; and, c) it performs routine assays of cytokines, other inflammatory mediators, proteases and protease inhibitors on bronchoscopy samples and on other samples provided by Center investigators. The Core provides sensitive, reliable, cost effective assays, maintaining high quality control and standardization. By having these functions provided by this Core, the utilization of invaluable patient material is optimized, interaction among investigators is stimulated, and the highest standards of clinical and analytic procedures are maintained while keeping costs at a minimum.

Project Start
1998-09-30
Project End
1999-03-31
Budget Start
Budget End
Support Year
16
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Lai, Nicola; M Kummitha, China; Rosca, Mariana G et al. (2018) Isolation of mitochondrial subpopulations from skeletal muscle: Optimizing recovery and preserving integrity. Acta Physiol (Oxf) :e13182
Donnola, Shannon B; Dasenbrook, Elliott C; Weaver, David et al. (2017) Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients. J Cyst Fibros 16:283-290
VanDevanter, D R; Flume, P A; Morris, N et al. (2016) Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:783-790
Jiang, Kai; Jiao, Sen; Vitko, Megan et al. (2016) The impact of Cystic Fibrosis Transmembrane Regulator Disruption on cardiac function and stress response. J Cyst Fibros 15:34-42
Bruscia, Emanuela M; Bonfield, Tracey L (2016) Cystic Fibrosis Lung Immunity: The Role of the Macrophage. J Innate Immun 8:550-563
Hsu, Daniel; Taylor, Patricia; Fletcher, Dave et al. (2016) Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation. Infect Immun 84:2410-21
Rymut, Sharon M; Kampman, Claire M; Corey, Deborah A et al. (2016) Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol 311:L317-27
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87
Darrah, Rebecca; Nelson, Rebecca; Damato, Elizabeth G et al. (2016) Growth Deficiency in Cystic Fibrosis Is Observable at Birth and Predictive of Early Pulmonary Function. Biol Res Nurs 18:498-504
VanDevanter, Donald R; Morris, Nathan J; Konstan, Michael W (2016) IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 15:372-9

Showing the most recent 10 out of 445 publications